Waterloo Capital L.P. Has $1.32 Million Position in Chemed Co. (NYSE:CHE)

Waterloo Capital L.P. increased its stake in shares of Chemed Co. (NYSE:CHEFree Report) by 1.1% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,252 shares of the company’s stock after purchasing an additional 25 shares during the quarter. Waterloo Capital L.P.’s holdings in Chemed were worth $1,317,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Wealth Alliance grew its holdings in shares of Chemed by 3.0% during the fourth quarter. Wealth Alliance now owns 578 shares of the company’s stock worth $338,000 after purchasing an additional 17 shares during the last quarter. Legacy Wealth Asset Management LLC increased its position in Chemed by 0.9% in the 4th quarter. Legacy Wealth Asset Management LLC now owns 2,275 shares of the company’s stock valued at $1,330,000 after acquiring an additional 21 shares during the period. Signaturefd LLC raised its stake in shares of Chemed by 5.8% during the fourth quarter. Signaturefd LLC now owns 385 shares of the company’s stock valued at $225,000 after acquiring an additional 21 shares during the last quarter. Kestra Advisory Services LLC lifted its holdings in shares of Chemed by 3.8% during the third quarter. Kestra Advisory Services LLC now owns 634 shares of the company’s stock worth $329,000 after purchasing an additional 23 shares during the period. Finally, Covestor Ltd grew its stake in shares of Chemed by 27.4% in the third quarter. Covestor Ltd now owns 144 shares of the company’s stock worth $75,000 after purchasing an additional 31 shares during the last quarter. Institutional investors own 95.85% of the company’s stock.

Chemed Stock Performance

Shares of CHE stock traded down $0.51 during mid-day trading on Friday, hitting $543.66. The company’s stock had a trading volume of 56,430 shares, compared to its average volume of 74,239. The company has a market cap of $8.23 billion, a PE ratio of 29.26, a P/E/G ratio of 2.22 and a beta of 0.46. The company’s fifty day simple moving average is $581.59 and its 200-day simple moving average is $592.66. Chemed Co. has a 52 week low of $492.84 and a 52 week high of $654.62.

Chemed (NYSE:CHEGet Free Report) last issued its quarterly earnings results on Wednesday, April 24th. The company reported $4.68 earnings per share (EPS) for the quarter, missing the consensus estimate of $5.09 by ($0.41). The business had revenue of $589.23 million during the quarter, compared to analyst estimates of $587.18 million. Chemed had a net margin of 12.36% and a return on equity of 30.52%. On average, equities analysts anticipate that Chemed Co. will post 21.72 earnings per share for the current year.

Chemed Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 18th. Stockholders of record on Thursday, May 30th will be given a dividend of $0.40 per share. The ex-dividend date of this dividend is Thursday, May 30th. This represents a $1.60 dividend on an annualized basis and a dividend yield of 0.29%. Chemed’s dividend payout ratio (DPR) is presently 8.61%.

Wall Street Analysts Forecast Growth

Several brokerages have commented on CHE. Royal Bank of Canada cut their target price on Chemed from $712.00 to $697.00 and set an “outperform” rating on the stock in a report on Tuesday, May 21st. Oppenheimer increased their target price on shares of Chemed from $625.00 to $650.00 and gave the company an “outperform” rating in a research report on Thursday, February 29th. Finally, StockNews.com upgraded shares of Chemed from a “hold” rating to a “buy” rating in a research report on Saturday, May 4th.

Get Our Latest Stock Analysis on CHE

Insider Transactions at Chemed

In related news, VP Brian C. Judkins sold 11,158 shares of the company’s stock in a transaction that occurred on Wednesday, March 20th. The stock was sold at an average price of $645.00, for a total transaction of $7,196,910.00. Following the transaction, the vice president now directly owns 1,422 shares of the company’s stock, valued at approximately $917,190. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In other news, EVP Spencer S. Lee sold 2,000 shares of Chemed stock in a transaction dated Thursday, March 28th. The shares were sold at an average price of $641.65, for a total transaction of $1,283,300.00. Following the completion of the transaction, the executive vice president now directly owns 20,760 shares in the company, valued at $13,320,654. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Brian C. Judkins sold 11,158 shares of the company’s stock in a transaction dated Wednesday, March 20th. The stock was sold at an average price of $645.00, for a total transaction of $7,196,910.00. Following the completion of the sale, the vice president now owns 1,422 shares in the company, valued at approximately $917,190. The disclosure for this sale can be found here. Insiders have sold 21,308 shares of company stock valued at $13,270,946 in the last 90 days. 3.32% of the stock is currently owned by corporate insiders.

Chemed Profile

(Free Report)

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.

Read More

Institutional Ownership by Quarter for Chemed (NYSE:CHE)

Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.